PedAM
Pediatric Disease Annotations & Medicines
| papillary carcinoma | ||||
| Disease ID | 1529 |
|---|---|
| Disease | papillary carcinoma |
| Manually Symptom | (Waiting for update.) |
| Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:2) |
Manually Genotype(Total Text Mining Genotypes:0) |
|---|
| (Waiting for update.) |
All Snps(Total Genotypes:16) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
| rs113488022 | 17685465 | 673 | BRAF | umls:C0007133 | BeFree | BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. | 0.08556525 | 2007 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 17685465 | 1027 | CDKN1B | umls:C0007133 | BeFree | BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. | 0.006534468 | 2007 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 25894433 | 673 | BRAF | umls:C0007133 | BeFree | The BRAF V600E mutation was detected in 68 % (71/104) of papillary carcinoma cases and 78 % (7/9) of anaplastic carcinoma cases. | 0.08556525 | 2015 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 17714762 | 673 | BRAF | umls:C0007133 | BeFree | The missense point mutation BRAF(V600E) was identified in 42% (13/31 cases) of papillary carcinomas and 33% (5/15 cases) of undifferentiated carcinomas but not in normal thyroid tissues, nodular hyperplasia, follicular adenomas, or follicular carcinomas. | 0.08556525 | 2007 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 17520704 | 673 | BRAF | umls:C0007133 | BeFree | Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. | 0.08556525 | 2007 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 17453004 | 673 | BRAF | umls:C0007133 | BeFree | In summary, BRAF V600E mutation was occasionally observed in anaplastic carcinomas with papillary carcinoma, and the low frequency of BRAF V600E mutation in anaplastic carcinoma was thought to be due to the low frequency of anaplastic carcinomas with papillary carcinoma. | 0.08556525 | 2007 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 19415957 | 673 | BRAF | umls:C0007133 | BeFree | The T1799A BRAF mutation is absent in cribriform-morular variant of papillary carcinoma. | 0.08556525 | 2009 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 18840924 | 673 | BRAF | umls:C0007133 | BeFree | These findings indicate that, although BRAF(V600E) mutation may play some roles in local carcinoma development, there is no evidence that BRAF(V600E) mutation significantly reflects the aggressive characteristics and poor prognosis of patients with papillary carcinoma in Japan. | 0.08556525 | 2009 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 25879531 | 673 | BRAF | umls:C0007133 | BeFree | Cells derived from papillary carcinoma harboring the mutant BRAF (V600E) allele were slightly more sensitive to sorafenib than those harboring wildtype BRAF. | 0.08556525 | 2015 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 21403618 | 673 | BRAF | umls:C0007133 | BeFree | PTC with any RET/PTC rearrangements had more aggressive behavior than BRAF(V600E)-positive tumors or PTC without gene alterations. | 0.08556525 | 2010 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 17685465 | 10519 | CIB1 | umls:C0007133 | BeFree | BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. | 0.000814326 | 2007 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 16555627 | 673 | BRAF | umls:C0007133 | BeFree | In our series, BRAF mutation was detected exclusively in papillary carcinoma (54%), and was exclusively V599E (a single nucleotide change of A-T at nucleotide 1796). | 0.08556525 | 2005 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 19534623 | 673 | BRAF | umls:C0007133 | BeFree | After molecular analysis, the BRAF V600E mutation was detected in 18/32 (56.2%) cases with a cytology of suspicious for papillary carcinoma and 41/56 (73.2%) with PTC. | 0.08556525 | 2009 | BRAF | 7 | 140753336 | A | T,G,C |
| rs113488022 | 24574369 | 673 | BRAF | umls:C0007133 | BeFree | A high percentage of both melanomas and papillary carcinomas of the thyroid harbors a recurrent mutation (i.e., BRAF(V600E) ) in the BRAF oncogene. | 0.08556525 | 2013 | BRAF | 7 | 140753336 | A | T,G,C |
| rs11554290 | 14508525 | 4893 | NRAS | umls:C0007133 | BeFree | NRAS mutation was observed in six cases (6%), all in histological types other than papillary carcinoma, and was exclusively Q61R. | 0.007372538 | 2003 | NRAS | 1 | 114713908 | T | G,C,A |
| rs77543610 | 24817968 | 2263 | FGFR2 | umls:C0007133 | BeFree | Our data demonstrate that the recently reported association between early-onset papillary carcinoma of the bladder with germ line FGFR2 p.Pro253Arg mutation could not be found in our cohorts of sporadic bladder tumors. | 0.000542884 | 2014 | FGFR2 | 10 | 121520160 | G | C |
GWASdb Annotation(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
GWASdb Snp Trait(Total Genotypes:0) | |
|---|---|
| (Waiting for update.) | |
Mapped by lexical matching(Total Items:0) |
|---|
| (Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
|---|
| (Waiting for update.) |
Chemical(Total Drugs:1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
| C0007133 | arsenic trioxide | C006632 | 1327-53-3 | carcinoma, papillary | MESH:D002291 | therapeutic | 19014326 | ||
FDA approved drug and dosage information(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |
FDA labeling changes(Total Drugs:0) | |
|---|---|
| (Waiting for update.) | |